Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease

Maria Maddalena Laterza¹, Bruno Chiurazzi², MariaFiorella Brangi², Ferdinando Riccardi², and Giacomo Carteni²

¹Department of Medical Oncology Studies, Second University of Naples; ²Oncology Unit, Antonio Cardarelli Hospital, Naples, Italy

ABSTRACT

Gefitinib is a tyrosine kinase inhibitor, indicated in advanced non-small cell lung cancer in all lines of treatment for patients harboring EGFR mutations. It has a favorable toxicity profile but may induce unexpected adverse effects, such as an inflammatory reaction in the bladder. We report a rare case of hemorrhagic cystitis, an unusual side effect, in a patient with non-small cell lung cancer treated with gefitinib, which did not compromise the clinical response.